You just read:

ACT Announces UCLA Institutional Review Board (IRB) Approval of its Phase 1/2 Clinical Trials using hESC-Derived RPE Cells for the Treatment of Macular Degeneration

News provided by

Advanced Cell Technology, Inc.

Apr 28, 2011, 08:00 ET